Led research projects on pathogen epidemiology, molecular evolution, human genetic susceptibility to infectious disease, and novel meningococcal vaccine design.Pollard AJ, Ochnio J, Ho M et al. Disease susceptibility to ST11 complex meningococci bearing serogroup C or W135 polysaccharide capsules, North America. Emerging Infectious Diseases 2004; 10: 1812–5.Callaghan MJ, Jolley KA, Maiden MC. Opacity associated adhesin repertoire in hyperinvasive Neisseria meningitidis. Infection and Immunity 2006; 74: 5085–94.Bayliss CD, Callaghan MJ, Moxon ER. High allelic diversity in the methyltransferase gene of a phase variable type III restriction-modification system has implications for the fitness of Haemophilus influenzae. Nucleic Acids Research 2006; 34: 4046–59.Callaghan MJ, Rockett K, Banner C et al. Haplotypic diversity in human CEACAM genes: effects on susceptibility to meningococcal disease. Genes and Immunity 2008; 9: 30-7. Pulickal AS, Hambleton S, Callaghan MJ et al. Biliary cirrhosis in a child with inherited interleukin-12 deficiency. Journal of Tropical Paediatrics 2008; 54: 269–71.Callaghan MJ, Buckee CO, Jolley KA et al. The effect of immune selection on the structure of the meningococcal Opa protein repertoire. PLoS Pathogens 2008; 4: e1000020.Bennett JS, Callaghan MJ, Derrick JP et al. Variation in the Neisseria lactamica Porin and its Relationship to Meningococcal PorB. Microbiology 2008; 154: 1525–34.Callaghan MJ, McCarthy ND, Jolley KA et al. The Opa protein repertoires of disease-causing and carried meningococci: genetic diversity and association with clinical severity. Journal of Clinical Microbiology 2008; 46: 3033–41.Callaghan MJ, Lewis S, Sadarangani M et al. Potential of recombinant Opa proteins as vaccine candidates against hyperinvasive meningococci. Infection and Immunity 2011; 79: 2810–18.

Industrial placement year during B.Sc. Medeva Group Development, Liverpool, (July 1997-August 1998), Analytical Development Team (Protein Characterisation)